Shamburg News · 8-K filed Nov 16, 2026, 9:15 AM EST
Jaguar Health Reports Third Quarter 2026 Financial Results
JAGX · Jaguar Health, Inc.
- Earnings
- Materiality: high
Jaguar Health, Inc. reported third quarter 2026 results on November 16, 2026, furnished as Exhibit 99.1. Total net revenue was $2,343 thousand, compared with $3,083 thousand a year earlier, and net loss was $5,830 thousand, or $(9.23) per basic and diluted share, compared with a net loss of $9,648 thousand. The company cited the January 2026 licensing agreement with Future Pak, under which Future Pak became the exclusive U.S. marketer of Mytesi and Canalevia-CA1, and stated it reduced its outstanding debt balance by $10.1 million in Q3 2026.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-462345.
Written from the filing by Shamburg Markets. Figures are as reported by the company.